Dr Kevin M. Koo

Senior Research Fellow

UQ Centre for Clinical Research
Faculty of Medicine


Dr Kevin M. Koo is currently a National Health and Medical Research Council (NHMRC) Investigator Fellow at The University of Queensland Centre for Clinical Research (UQCCR). Dr Koo was awarded his PhD (Dean’s Award for Outstanding Thesis) from the Australian Institute for Bioengineering & Nanotechnology (AIBN), UQ in 2018. His PhD research was on the molecular analysis of nucleic acid biomarkers in prostate cancer liquid biopsies (with a particular interest in fusion genes), and the development of associated nanotechnology-based biosensors to facilitate precision cancer treatment.

Post-PhD, he begun a productive postdoctoral career with dual industry/academia appointments: as the Head of Assay Development/Lab Director in XING Technologies Pty Ltd (a Brisbane-based biotech start-up) to undertake product development projects for commercialization of disease in vitro diagnostics, and as an Honorary Fellow/Principal Research Scientist at UQCCR to continue his academic research in precision cancer nanodiagnostics. His research skills and experiences are honed through dedicated career time spent in both academic research and regulated industry environments.

Dr Koo's research encompasses multi-disciplinary fields of molecular biomarker and nanobiosensor development, translation, and commercialization for precision disease management applications. Presently, he is working on the design and development of integrated multi-bioanalyte sensing technologies to resolve the various challenges around holistic disease biomarker pathway understanding and disease detection.

Dr Koo's research endeavours have been recognized by a Metrohm Australia-New Zealand Young Chemist Award (2018), Springer Thesis Award (2019) and Queensland Young Tall Poppy Science Award (2023).

Research Interests

  • Molecular Diagnostics/In Vitro Diagnostics
  • Nanobiosensors
  • Liquid Biopsy
  • Photonics
  • Electrochemistry

Research Impacts

To date, Dr Koo's research has contributed Knowledge Impact by:

  1. Developing point-of-need nanobiosensors for prostate cancer-specific urinary biomarkers (Koo KM et al., Nature Reviews Urology, 2019; Dey et al., Small, 2018)
  2. Progressing nanobiosensor clinical translation for precision cancer management (Koo KM et al., ACS Nano, 2018)
  3. Addressing key assay challenges around circulating biomarker detection in cancer liquid biopsies (Koo KM & Trau M, ACS Sensors, 2020)

Dr Koo's specialist knowledge in his fields of research expertise has led to global invitations for scientific evaluation. He is an Associate Editor for Frontiers in Nanotechnology (2022-present) and regular Peer Reviewer (30+ reviews/yr) for 20+ leading journals of worldwide publishers American Chemical Society, Royal Society of Chemistry, Wiley-VCH, and Elsevier. He is an international Assessor for external quality assessment (EQA) organizations European Molecular Genetics Quality Network (EMQN) and Genomics Quality Assessment (GenQA) (2022-Present), evaluating 20+ clinical sequencing labs/yr worldwide participating in EQA schemes for technical and regulatory compliance.

Dr Koo is passionate about science communication and outreach activities to impact the broader community, especially by leveraging his unique academic/industry track record to champion diverse STEM career pathways. He volunteers as an Industry Mentoring Networking in STEM (IMNIS) Mentor to motivated early- and mid-career researchers (3 to date) for career and professional development mentoring.


  • Doctor of Philosophy, The University of Queensland
  • Bachelor (Honours) of Biochemistry, The University of Queensland
  • Bachelor of Biophysics, The University of Queensland


View all Publications



Book Chapter

Journal Article

Conference Publication

Other Outputs